In toxicity testing, each animal may have to be viewed as a surrogate for millions of people and should be examined as thoroughly as a human patient. However, there are many differences between human diagnosis and animal toxicity testing. Human diagnosis is primarily based on anamnesis, symptoms, and utilization of a huge database of diseases. However, in animal toxicity testing, clinical and anatomical pathology data are usually a primary source of toxicity information, even though the positive endpoints are generally not known in advance and the number of positive toxicity endpoints may be numerous. This situation will generate at least 2 practical problems in clinical pathology testing: (1) how to preselect test items without precise knowledge of toxicity endpoints and (2) how to handle multiple data sets for toxicity detection. The latter includes issues of inflation of the overall false-positive rate and multicomparison problems. A "disease" called "significantosis" and a concept of integrated interpretation of multiple biologically related items to avoid false-positive judgments and unnecessary censoring of meaningful outlier data are briefly discussed. In general, toxicity tests are quite exploratory and the endpoints are unknown and multiple, so the procedures for data interpretation should be determined on a case-by-case basis. Construction of toxicity entity-oriented databases may be a requirement for further refinement of toxicity study interpretation.
It is a great honor to have an opportunity to participate in this workshop concerning regulatory aspects of clinical pathology in prechronic studies. My present affiliation in Japan is a university medical school, which is administratively under the Ministry of Education, Science and Culture, but not the Ministry responsible for food and drug regulation. Thus, from a bureaucratic point of view, I am an outsider in the field of regulatory issues; however, I have had an opportunity to participate in research work relevant to such regulatory processes with Dr. Yuzo Hayashi, National Institute of Hygienic Sciences (NIHS), Tokyo, and my presentation here is based mostly on input from Dr. Hayashi and on my own experience at the NIHS. I will attempt to cover the fundamental viewpoint of the majority of Japanese scientists participating in regulatory issues for evaluation of toxicity studies.
To begin, I would like to quote 2 sentences from a textbook for toxicity testing. These are, &dquo;therefore, each animal may be viewed as a surrogate for mil-lions of people,&dquo; and &dquo;it is essential that the maximum amount of valid information be obtained from each animal&dquo; (1). I believe that these statements represent a fundamental viewpoint to be taken for toxicity studies. In other words, these statements mean that we must try to treat and examine each animal as a human patient in any toxicity studies.
It is obvious, however, that there are many differences between treating human patients in hospitals and handling test animals for toxicity testings in laboratories. Table I summarizes the differences in diagnostic procedures for humans and animals. In most human cases, large amounts of information obtained from anamnesis and symptoms may allow preliminary diagnosis and, in general, clinical pathology testing, and pathological examinations are performed to confirm or improve such preliminary diagnosis. The final diagnosis is usually made by contrasting overall profiles of the patient to a huge database of diseases.
In the process of animal testing for desired pharmaceutical effects, information derived from chemical structure of the compound or from the in vitro experiments could be used to characterize the compound as a medical drug. This situation may correspond to the careful taking of anamnesis for diagnosis of a human patient. Thereafter, the most However, in the process of detecting any nondesired effects or toxicities, investigators must be prepared to cope with all kinds of potential adverse effects of the chemical. In other words, when you are looking for toxicity, in general, the endpoints are not known, but the number of endpoints appears to be numerous. This situation will generate at least 2 practical problems in the field of clinical pathology testing for toxicity. One is the problem of how to predetermine test items without precise knowledge of toxicity endpoints. The second problem is how to handle multiple data sets in order to define the toxic effects. I would like to make some comments on these 2 problems.
It is likely that there are 3 possible choices for the selection of clinical pathology tests in toxicity studies. The first choice is to consider reasonable tests according to common sense, keeping specimens for additional tests needed. The second choice is to perform a large battery of tests regardless of the cost. The last choice is to ask regulatory agencies to select the clinical pathology tests.
A common sense approach consists of 3 factors (Table II) : The first factor is whether or not the items are routinely measured in human beings, the second is whether or not measurement of the items is useful to monitor vital or maj or metabolic organs, and the third is the factor of cost/benefit or cost/effectiveness balance. In consideration of these factors, most investigators are monitoring hematology, liver function, renal function, and muscle-related enzymes as a set of predetermined tests.
A few regulators still tend to require data for all possible tests regardless of cost or benefit, while some company investigators wish to have information or recommendations from the regulatory agencies on the items to be measured. According to my understanding, however, the recommendations from the regulatory agencies appearing in the guideline booklet will be a set of rather simple statements totally based on common sense as already mentioned. So, the probable statements from the regulatory agencies for any questions concerning the recommendations in the guideline are likely to be &dquo;recommendations are not mandatory, and the interpretation of the data is totally dependent on each investigator,&dquo; &dquo;most of the tests recommended in the guideline are utilized as supportive for histopathologic and pharmacological data,&dquo; or &dquo;these are usually not specific enough to assess mechanisms of toxicity, but are sensitive parameters indicating the presence of toxicity and may sometimes be more sensitive than histopathological examinations, and may serve as a good parameter for comparing toxicity of different chemicals among different experiments.&dquo;
The second issue in toxicity testing is the multiplicity of the data. Multiplicity problems in calculating statistical significance include at least 2 categories : inflation of the overall false-positive rate and multicomparison.
From a statistical viewpoint, it is well known that when n independent items are tested at a significance level of a, the overall false-positive rate is given by 1 -( 1 -«)n, which gives a 79% false-positive rate only by chance with a of 5% and n of 30. There are many statistical proposals to reduce this rate, such as Bonferroni and Dunnet, but there are still debates about each of them.
A problem in the regulatory environment that is related to this statistical issue is a &dquo;disease&dquo; called &dquo;significantosis.&dquo; (Note: I first heard this term from Dr. Akira Sakuma, Professor of Department of Clinical Pharmacology, Medical Research Institute, Tokyo Medical & Dental University.) The principal symptom of this &dquo;disease&dquo; is that once the patient is confronted with a data set with a p-value smaller than 0.05, then he or she instantly believes that it is definitely biologically significant. Fortunately, this &dquo;disease&dquo; is not highly prevalent, and regulatory agencies have been successful in avoiding such judgments.
Between the statistical analysis of individual raw data and the final assessment of biological signifi-
FiG. Example of changes in the graphic patterns of response of the hematopoitic system to various toxins: A) normochromic anemia, B) hemoconcentration or polycythemia; C) hyperchromic anemia or possible megaloblastic anemia; and D) a very unusual pattern, probably a result of a severe red cell fragmentation with spherocytosis possibly resulting in a slightly elevated MCHC. See text for details. cance of the toxicity tests, there is an intermediate 1 phase of looking at the raw data. This is an inte-: grated interpretation of multiple items. (Fig. 1 ) . It is our experience that < changes in the graphic pattern provide a much better j , TABLE IIL-Example: red blood cell count. ' understanding of the nature of toxicity and a better sensitivity for the presence of chemical toxicity than looking at individual items on separate tables. For example, the upper left (A) in Fig. 1 shows a chemical compound inducing normochromic anemia (i.e., decrease in red blood cells, hemoglobin, and hematocrit and no change in the 3 ratios); (B) shows a pattern interpreted as hemoconcentration of polycythemia, where red blood cells, hemoglobin, and hematocrit are increasing but the 3 ratios are not changing; (C) shows a pattern of hyperchromic anemia or possible megaloblastic anemia; and (D) shows a very unusual pattern, probably a result of a severe red cell fragmentation with spherocytosis possibly resulting in a slightly elevated mean corpuscular hemoglobin concentration.
These kinds of analyses based on combination of closely related items are routinely performed by scientists in the process of toxicity evaluation since this process is very important for detecting true biological effect, reducing the false-positive rate, and FIG. 2.-An example of the unexpected heterogeneity that can occur with inbred animals. A) When an experiment is done with doses 0, 1, and 2, measurement of a particular response for an animal in dose 2 (indicated with an arrow) looks like an outlier. B) When the data of the dose 3 group are shown, the interpretation of the same response changes from &dquo;an outlier&dquo; to &dquo;a good indicator of toxicity.&dquo; treating &dquo;significantosis.&dquo; However, in an attempt to analyze statistical significance of changes in combined items, one usually encounters many unsolved problems of multicomparisons. It may be easy to address a null hypothesis (Ho) such as &dquo;there is no change in pattern (or something like Ho : ~i ~ &dquo; -= An), but major problems may be associated with addressing the antithesis (HI) and in determining how to calculate type 2 error for H 1. In Japan, at least one biostatistical society is working on these kinds of issues, and it is likely that good databases, especially toxicity-oriented ones, are needed for this problem.
Inbred animals are often heterogeneous enough to surprise statisticians by showing large variances far beyond those predicted by binomial distributions. Thus, extreme caution is needed to distinguish measurement errors from biological variations. As shown in Fig. 2A , when an experiment is done with doses 0, 1, and 2, measurement of a particular response for an animal in dose 2 (indicated with an arrow) looks like an outlier. However, if the data of the dose 3 group were shown (Fig. 2B) , interpretation of the same dose 2 response changes from &dquo;an outlier&dquo; to &dquo;a good indicator of toxicity.&dquo; To avoid misidentification of outliers and unnecessary censoring, data analysis on individual animals may sometimes be needed instead ofroutine group-based statistical analysis using a program equipped with an automatic &dquo;outlier detector.&dquo;
In summary, I should emphasize that toxicity tests are more exploratory, while drug tests for effectiveness are more confirmatory. In exploratory studies where endpoints are often unexpected and multiple, the procedures for data interpretation should be determined on a case-by-case basis. In addition, to get to an appropriate interpretation, we need referable databases. Construction of databases for both control animals and treated animals, particularly for toxicity entity-oriented databases, may be required for further refinement of toxicity study interpreta- 
